Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a dpp-4 inhibitor in sirs and/or sepsis

a dpp4 inhibitor and sepsis technology, applied in the field of dpp4 inhibitors, can solve the problems of microcirculatory dysfunction, abnormal coagulation and blood flow, excessive inflammation or immunosuppression, etc., and achieve the effect of reducing the risk

Inactive Publication Date: 2013-11-14
BOEHRINGER INGELHEIM INT GMBH
View PDF4 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a certain medication (linagliptin) that can help treat, prevent, and reduce the risk of sepsis, a severe infection that can damage multiple organs and cause death. The medication can be used alone or in combination with other medications. The technical effect is that this medication can help treat and prevent sepsis, a potentially life-threatening infection.

Problems solved by technology

The nature of the interactions between the microbial pathogen and the host is complex and, at the tissues, results in excessive inflammation or immunosuppression, abnormal coagulation and blood flow, and microcirculatory dysfunction leading to organ injury and cell death.
On the other hand, patients suffering from sepsis in a later status consistently show a decline in their immune responsiveness (immune deficiency of the adaptive immune system).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a dpp-4 inhibitor in sirs and/or sepsis
  • Use of a dpp-4 inhibitor in sirs and/or sepsis
  • Use of a dpp-4 inhibitor in sirs and/or sepsis

Examples

Experimental program
Comparison scheme
Effect test

examples

Survival of Septic Rats with and without Linagliptin Treatment

[0281]Female Wistar rats are fed a diet containing 0.083 mg / kg linagliptin (corresponding to 50-150 nM mean plasma concentration) for 6 day or control diet. Animals are injected at day 2 with 10 mg / kg LPS (lipopolysaccharide) i.p. and observed for 4 additional days.

[0282]Three groups of female Wistar rats are compared with respect to proportion surviving 24 hours LPS (lipopolysaccharide, 10 mg / kg i.p.) treatment using Fisher's exact test for 2 by 3 tables (p=0.004), and additionally, group b and c are compared using Fisher's two-sided exact test for 2 by 2 tables (p=0.015, LPS vs. LPS+Linagliptin). It should be noted that the survival curve only represents preliminary data (“pseudo Kaplan-Meier-curve”) since the exact time point of death of the rats is not assessed. The female Wistar rats are injected with LPS in the morning, monitored during the day and transferred back to the stable in the evening. Deaths are registered...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
waist circumferenceaaaaaaaaaa
waist circumferenceaaaaaaaaaa
waist circumferenceaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for treating and / or preventing SIRS and / or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of SIRS and / or sepsis.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a certain DPP-4 inhibitor (preferably linagliptin, optionally in combination with one or more other active agents) for use in treating, preventing and / or reducing the risk or likelihood of systemic inflammatory response syndrome (SIRS) and / or sepsis (SIRS / sepsis) and / or diseases related or associated therewith, to pharmaceutical compositions and combinations comprising such active components, and to certain therapeutic uses thereof.[0002]Further, the present invention relates a certain DPP-4 inhibitor (preferably linagliptin, optionally in combination with one or more other active agents) for use in treating, preventing and / or and / or reducing the risk of SIRS / sepsis, which is one or more selected from septic or non-septic SIRS, severe SIRS / sepsis, SIRS / septic shock and multi-organ failure associated with SIRS / sepsis.[0003]Further, the present invention relates a certain DPP-4 inhibitor (preferably linagliptin, optionally i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D473/06A61K45/06A61K31/522
CPCC07D473/06A61K31/522A61K45/06A61K31/4985A61K31/5025A61K31/519A61P1/16A61P13/02A61P13/12A61P15/00A61P19/10A61P25/00A61P25/28A61P27/02A61P29/00A61P3/00A61P3/04A61P31/00A61P31/04A61P3/06A61P43/00A61P9/00A61P9/10A61P9/12A61P3/10A61K2300/00
Inventor KLEIN, THOMASDAIBER, ANDREASDUGI, KLAUSMARK, MICHAELMUENZEL, THOMAS
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com